Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia clinical trial analysis report delivers important insights into ongoing research of 25+ pipeline chronic myeloid leukemia drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia clinical trial analysis report delivers important insights into ongoing research of 25+ pipeline chronic myeloid leukemia drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Chronic Myeloid Leukemia Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for chronic myeloid leukemia across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the chronic myeloid leukemia domain.

Chronic Myeloid Leukemia Clinical Trial Analysis Summary

• DelveInsight’s chronic myeloid leukemia pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline chronic myeloid leukemia drugs. 
• Key chronic myeloid leukemia companies, such as Merck & Co., Inc., Enliven Therapeutics, ImmunoForge, Renascience, MacroGenics, Gilead Sciences, Mendus AB, Shenzhen TargetRx Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, Crossbow Therapeutics, Inc., Shenzhen Zhenxing Medical Technology, and others, are evaluating new chronic myeloid leukemia drugs to improve the treatment landscape.
• Promising pipeline chronic myeloid leukemia therapies, such as TERN-701, ELVN-001, KF 1601, RS 5614, MGD024, Vididencel, TGRX-678, TQB3911, CBX-250, CUDC 201, and others, are in different phases of chronic myeloid leukemia clinical trials.
• Approximately 7+ chronic myeloid leukemia drugs are in the late and mid stages of development.
• Notable MoAs in chronic myeloid leukemia clinical trials include Plasminogen activator inhibitor-1 inhibitor, BCR-ABL tyrosine kinase inhibitor, Anti-CD123 × CD3, and others.

Request a sample and discover the recent advances in chronic myeloid leukemia treatment @ https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-pipeline-insight

What is Chronic Myeloid Leukemia?

Chronic myeloid leukemia (CML) is a type of blood cancer that develops in the bone marrow and primarily affects the myeloid cells responsible for producing blood cells. It is characterized by the abnormal growth of white blood cells and is most commonly associated with a genetic change known as the Philadelphia chromosome, which results from the fusion of the BCR and ABL1 genes. This fusion produces the BCR-ABL1 protein, an abnormal tyrosine kinase that promotes uncontrolled cell growth. CML typically progresses through three phases, chronic, accelerated, and blast phase, with most patients diagnosed during the chronic phase. The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, has significantly improved treatment outcomes and transformed CML into a largely manageable chronic condition for many patients.

Find out more about treatment for chronic myeloid leukemia @ Chronic Myeloid Leukemia New Treatment

A snapshot of the Pipeline Chronic Myeloid Leukemia Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
RS 5614	Renascience	III	Plasminogen activator inhibitor-1 inhibitor	Oral
TERN-701	MSD	I/II	BCR-ABL tyrosine kinase inhibitor	Oral
MGD024	MacroGenics/Gilead Sciences	I	Anti-CD123 × CD3	Intravenous
ELVN-001	Enliven Therapeutics	I	Bcr-Abl tyrosine kinase inhibitor	Oral
KF 1601	ImmunoForge	I	Bcr-Abl tyrosine kinase	Oral

Learn more about the chronic myeloid leukemia latest research @ Chronic Myeloid Leukemia Clinical Trials 

As Stuti Mahajan, consulting manager at DelveInsight, chronic myeloid leukemia is driven by the BCR::ABL1 fusion, with tyrosine kinase inhibitors (TKIs) transforming it into a largely manageable long-term disease. The market is evolving from established TKI therapies toward newer, more selective agents and treatment strategies aimed at addressing resistance, intolerance, deeper molecular responses, and treatment-free remission, supporting continued innovation despite a mature treatment landscape.

Recent Developments in Chronic Myeloid Leukemia Treatment Space

• In June 2026, Enliven Therapeutics, Inc. presented updated positive data from the Phase I ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML).
• In July 2026, Mendus AB announced successful recruitment of the first stage of the VITAL-CML trial, comprising the first 8 patients. This marks an important milestone in the development of the company’s lead product vididencel in chronic myeloid leukemia (CML).
• In May 2026, Merck announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. The addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck’s oncology pipeline.
• In April 2026, Terns Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs.
• In April 2026, Mendus AB announced that the first patient has been enrolled in the VITAL-CML trial, which evaluates Mendus’ lead product vididencel in chronic myeloid leukemia (CML).
• In January 2025, ImmunoForge announced that it has received approval for the Phase I clinical trial IND for KF1601, a treatment for Chronic Myelogenous Leukemia (CML), from the Korea Ministry of Food and Drug Safety.

Scope of the Chronic Myeloid Leukemia Pipeline Report 

• Coverage: Global 
• Chronic Myeloid Leukemia Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Chronic Myeloid Leukemia Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Chronic Myeloid Leukemia Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Chronic Myeloid Leukemia Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Chronic Myeloid Leukemia Therapeutics Assessment By Mechanism of Action:  Plasminogen activator inhibitor-1 inhibitor, Bcr-Abl tyrosine kinase inhibitor, Anti-CD123 × CD3, and others
• Key Chronic Myeloid Leukemia Companies: Merck & Co., Inc., Enliven Therapeutics, ImmunoForge, Renascience, MacroGenics, Gilead Sciences, Mendus AB, Shenzhen TargetRx Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, Crossbow Therapeutics, Inc., Shenzhen Zhenxing Medical Technology and others.
• Key Chronic Myeloid Leukemia Pipeline Therapies: TERN-701, ELVN-001, KF 1601, RS 5614, MGD024, Vididencel, TGRX-678, TQB3911, CBX-250, CUDC 201 and others.

Dive deep into rich insights for chronic myeloid leukemia cure, visit @ Chronic Myeloid Leukemia News

Table of Contents

1.	Chronic Myeloid Leukemia Pipeline Report Introduction
2.	Chronic Myeloid Leukemia Pipeline Report Executive Summary
3.	Chronic Myeloid Leukemia Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Chronic Myeloid Leukemia Clinical Trial Therapeutics
6.	Chronic Myeloid Leukemia Pipeline: Late-Stage Products (Pre-registration)
7.	Chronic Myeloid Leukemia Pipeline: Late-Stage Products (Phase III)
8.	Chronic Myeloid Leukemia Pipeline: Mid-Stage Products (Phase II)
9.	Chronic Myeloid Leukemia Pipeline: Early-Stage Products (Phase I)
10.	Chronic Myeloid Leukemia Pipeline Therapeutics Assessment
11.	Inactive Products in the Chronic Myeloid Leukemia Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Chronic Myeloid Leukemia Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the chronic myeloid leukemia clinical trials, reach out @ Chronic Myeloid Leukemia Medication

Related Reports

Chronic Myeloid Leukemia Market

Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CML companies, including Enliven Therapeutics, Ascentage Pharma, Takeda Pharmaceuticals, Terns Pharmaceuticals, and others.

Chronic Phase Myeloid Leukemia Market

Chronic Phase Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic phase myeloid leukemia companies, including Novartis, Bristol Myers Squibb, Pfizer, Takeda Pharmaceutical, Otsuka Pharmaceutical, Incyte, Ascentage Pharma, Sun Pharmaceutical, Teva Pharmaceuticals, Aurobindo Pharma, Innovent Biologics, Cipla, Dr. Reddy’s Laboratories, Lupin, Amneal Pharmaceuticals, Viatris, Accord Healthcare, Il-Yang Pharmaceutical, Bio-Path Holdings, Orca Bio, and others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Daiichi Sankyo, Agios Pharma, Astellas Pharma, Rigel Pharmaceuticals, Jazz Pharmaceuticals, Novartis, Pfizer, Abbvie, BMS, Arog Pharmaceuticals, Actinium Pharmaceutical, Astex Pharmaceutical, Syndax, Geron, SELLAS Life Sciences, Johnson & Johnson Innovative Medicine, Sanofi, Affimed, Sumitomo Pharma, Kura Oncology, CULLINAN THERAPEUTICS, Molecular Partners, Caribou Biosciences, BioPath Holdings, and others.

Acute Myeloid Leukemia Clinical Trial Analysis 

Acute Myeloid Leukemia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Changzhou Qianhong Bio-pharma Co., Ltd., Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics, Lomond Therapeutics, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, and others.

Myelofibrosis Market

Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myelofibrosis companies, including PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679